WINDLAS

Windlas Biotech Share Price

₹923.45 -10.7 (-1.15%)

20 Jul, 2025 12:48

SIP TrendupStart SIP in WINDLAS

Start SIP

Performance

  • Low
  • ₹910
  • High
  • ₹943
  • 52 Week Low
  • ₹659
  • 52 Week High
  • ₹1,198
  • Open Price₹943
  • Previous Close₹934
  • Volume23,304

Investment Returns

  • Over 1 Month + 5.06%
  • Over 3 Month -14.82%
  • Over 6 Month -8.32%
  • Over 1 Year + 34.59%
SIP Lightning

Smart Investing Starts Here Start SIP with Windlas Biotech for Steady Growth!

Invest Now

Windlas Biotech Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 31.7
  • PEG Ratio
  • 6.6
  • Market Cap Cr
  • 1,936
  • P/B Ratio
  • 4.1
  • Average True Range
  • 30.41
  • EPS
  • 29.18
  • Dividend Yield
  • 0.6
  • MACD Signal
  • -2.88
  • RSI
  • 52.87
  • MFI
  • 73.65

Windlas Biotech Financials

Windlas Biotech Technicals

EMA & SMA

Current Price
₹923.45
-10.7 (-1.15%)
pointer
  • stock-down_img
  • Bearish Moving Average 6
  • stock-up_img
  • Bullish Moving Average 10
  • 20 Day
  • ₹913.72
  • 50 Day
  • ₹922.44
  • 100 Day
  • ₹932.04
  • 200 Day
  • ₹907.14

Resistance and Support

925.42 Pivot Speed
  • R3 973.03
  • R2 957.82
  • R1 940.63
  • S1 908.23
  • S2 893.02
  • S3 875.83

What's your outlook on Windlas Biotech?

You can only vote once!

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Windlas Biotech Ltd. is a pharmaceutical company specializing in contract development and manufacturing, producing a wide range of formulations, including tablets, capsules, and syrups. It serves both domestic and international markets with quality, affordable healthcare solutions.

Windlas Biotech has an operating revenue of Rs. 759.88 Cr. on a trailing 12-month basis. An annual revenue growth of 21% is outstanding, Pre-tax margin of 10% is healthy, ROE of 11% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 73 which is a FAIR score but needs to improve its earnings, a RS Rating of 47 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 79 indicates it belongs to a poor industry group of Medical-Ethical Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Windlas Biotech Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-22 Audited Results & Final Dividend
2025-02-11 Quarterly Results
2024-11-12 Quarterly Results
2024-08-13 Quarterly Results
2024-05-20 Audited Results & Dividend
Date Purpose Remarks
2025-07-21 FINAL Rs.5.80 per share(116%)Final Dividend
View More

Windlas Biotech F&O

Windlas Biotech Shareholding Pattern

62.34%
6.7%
1.52%
21.36%
8.08%

About Windlas Biotech

  • NSE Symbol
  • WINDLAS
  • BSE Symbol
  • 543329
  • Managing Director
  • Mr. Hitesh Windlass
  • ISIN
  • INE0H5O01029

Similar Stocks to Windlas Biotech

Windlas Biotech FAQs

Windlas Biotech share price is ₹923 As on 20 July, 2025 | 12:34

The Market Cap of Windlas Biotech is ₹1935.5 Cr As on 20 July, 2025 | 12:34

The P/E ratio of Windlas Biotech is 31.7 As on 20 July, 2025 | 12:34

The PB ratio of Windlas Biotech is 4.1 As on 20 July, 2025 | 12:34

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23